U.S., Feb. 6 -- ClinicalTrials.gov registry received information related to the study (NCT07391319) titled 'The Prospective, Double-blind, Multicenter, Placebo-controlled, Randomized, Comparative Clinical Trial' on Jan. 12.
Brief Summary: The main objective of the study is to evaluate the efficacy and safety of Neovasculgen(R) in a course dose of 2.4 mg in combination with standard drug therapy in patients with unilateral neuroischemic form of diabetic foot syndrome.
Study Start Date: Feb. 11, 2025
Study Type: INTERVENTIONAL
Condition:
Ulcer Foot
Mellitus Diabetes
Intervention:
DRUG: Neovasculgen(R)
The diluted drug will be administered by 5-10 injections intramuscularly twice with an interval of 14 days, in the course dosage mode -...